Global Healthcare Leader Deploys QUOSA's Literature Management Tools

Description

Global Healthcare Leader DeploysGlobal Healthcare Leader Deploys QUOSA's Literature Management Tools PR Newswire PHILADELPHIA, October 22, 2013 Sanofi will use QUOSA, part of Elsevier Life Science Solutions for drug discovery and development, to support adverse event monitoring Elsevier, a world-leading provider of scientific, technical and medical information products and services, today announced that Sanofi, one of the world's leading pharmaceutical organizations, has implemented QUOSA's literature management tools to automate adverse event monitoring. QUOSA powers the retrieval, storage, tagging and annotation of relevant case reports, allowing for the creation of a centralized repository of product- related scientific literature. This centralized repository supports Sanofi's Pharmacovigilance team in drug safety and adverse event monitoring, ensuring patient safety and compliance with regulatory reporting requirements in all the markets in which it operates. "Pharmaceutical companies are continually challenged to ensure regulatory compliance is met. This is no easy task with limited resources, an ever- growing number of literature articles and an increasing portfolio of drugs to be tracked. Left untamed, this presents significant risks in compliance and crucially, in patient safety," said Michael Rai, General Manager of QUOSA at Elsevier.

Informations

• Publié par: Elsevier
• Publié le: 22 octobre 2013
• Nombre de lectures: 17
• Langue: English

Extrait

Global Healthcare Leader Deploys QUOSA's Literature Management Tools

PR Newswire

PHILADELPHIA, October 22, 2013

Sanofi will use QUOSA, part of Elsevier Life Science Solutions for drug discovery and development, to support adverse event monitoring

Elsevier, a world-leading provider of scientific, technical and medical information products and services, today announced that Sanofi, one of the world's leading pharmaceutical organizations, has implemented QUOSA's literature management tools to automate adverse event monitoring. QUOSA powers the retrieval, storage, tagging and annotation of relevant case reports, allowing for the creation of a centralized repository of product-related scientific literature. This centralized repository supports Sanofi's Pharmacovigilance team in drug safety and adverse event monitoring, ensuring patient safety and compliance with regulatory reporting requirements in all the markets in which it operates.

"Pharmaceutical companies are continually challenged to ensure regulatory compliance is met. This is no easy task with limited resources, an ever-growing number of literature articles and an increasing portfolio of drugs to be tracked. Left untamed, this presents significant risks in compliance and crucially, in patient safety," said Michael Rai, General Manager of QUOSA at Elsevier. "In response to our many conversations with Information Professionals, we have finely tuned QUOSA to complement current processes to provide a stable, efficient and scalable solution which continues to evolve with future needs. We look forward to working with Sanofi to manage this flow of information and support its Pharmacovigilance teams' work."

QUOSA provides software and services to life science companies, enabling them to centralize repositories of scientific literature related to drugs and medical devices, as well as receive alerts about new articles related to their products and other market developments. These not only help Pharmacovigilance and Medical Affairs teams carry out their work effectively and quickly, they also ensure sound information management processes and compliance with regulatory requirements.

QUOSA's pharmacovigilance solution features three elements that help companies meet their literature tracking objectives. First, Elsevier provides prompt customized professional services through its dedicated Life Sciences Integration Services team. Second, QUOSA can be used as either a desktop application or browser-based technology, facilitating secure and scalable information sharing across multiple regions. Third, QUOSA easily integrates with already existing literature resources like third-party publisher platforms, A&I databases like Embase, and document delivery vendors.

QUOSA is part of Elsevier Life Science Solutions, a suite of interoperable, domain-specific, decision support tools which span the discovery and development workflow; including TargetInsights®, Pathway Studio™, Reaxys ®, Reaxys ® Medicinal Chemistry, PharmaPendium® and Embase®.

About Elsevier

Elsevier is a world-leading provider of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet and Cell, and close to 20,000 book titles, including major reference works from Mosby and Saunders. Elsevier's online solutions include ScienceDirect, Scopus, SciVal, Reaxys, ClinicalKey and Mosby's Suite, which enhance the productivity of science and health professionals, helping research and health care institutions deliver better outcomes more cost-effectively.

A global business headquartered in Amsterdam, Elsevier employs 7,000 people worldwide. The company is part of Reed Elsevier Group PLC, a world leading provider of professional information solutions. The group employs more than 30,000 people, including more than 15,000 in North America. Reed Elsevier Group PLC is owned equally by two parent companies, Reed Elsevier PLC and Reed Elsevier NV. Their shares are traded on the London, Amsterdam and New York Stock Exchanges using the following ticker symbols: London: REL; Amsterdam: REN; New York: RUK and ENL.

Media contact
Liz Griffioen
Elsevier
[phone]
[e-mail]